Press Releases

 
Press Releases
  Date Title View
Feb 23, 2017
DURHAM, N.C., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs, today announced that it will host a live conference call and audio webcast on Thursday, March 2, 2017 at 8:30 a.m. ET to report ...
Feb 22, 2017
-- Results show higher survival rate in adenovirus-infected patients with a virologic response to brincidofovir -- -- Mortality rates were lower in pediatric patients than in adult patients -- DURHAM, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced the presentation of final data from the AdVise trial of brincid...
Jan 6, 2017
Study confirms drug levels for IV BCV 10 mg equivalent to oral BCV 100 mg   No gastrointestinal side effects seen with IV BCV at 10 and 25 mg doses DURHAM, N.C., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromi...
Jan 5, 2017
DURHAM, N.C., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced the appointments of Randall Lanier, PhD, as Chief Science Officer and Roy W. Ware, PhD, MBA, as Chief Manufacturing and Tech...
Jan 4, 2017
DURHAM, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering and developing medicines that improve outcomes for immunocompromised patients, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the 35th Annual J.P. Morgan Healthca...
Nov 17, 2016
DURHAM, N.C., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering and developing medicines that improve outcomes for immunocompromised patients,  presented data from a preclinical study of intravenous (IV) brincidofovir to determine tissue distribution after single IV or oral administration of the dru...
Nov 9, 2016
DURHAM, N.C., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present a corporate overview at the following upcoming conferences: Sti...
Nov 7, 2016
- Brincidofovir IV Single and Multiple Dose Data Expected to Report Out in 2017 - - Comparative Adenovirus Trial with Oral Brincidofovir Expected to Start in 2017 - - CMX521 for Norovirus Advancing Toward the Clinic - - Conference Call at 8:30 a.m. ET Today - DURHAM, N.C., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopha...
Oct 31, 2016
DURHAM, N.C., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a live conference call and audio webcast on Monday, November 7, 2016 at 8:30 a.m. ET to report financial results for the third quarter ended Septemb...
Oct 27, 2016
- Results Show Early Virologic Response Associated with Better Overall Survival - DURHAM, N.C., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced the presentation of detailed 24-week interim results from the AdVise trial of br...
Page:
1
... NextLast
= add release to Briefcase